Docirbrutinib

N/A

Report date: 2024/12/27 14:09:22
NME

Base Information

Drug NameDocirbrutinib
Drug Alias NameMilrebrutinibAS-1763BN-102CB-1763
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsWaldenstrom MacroglobulinemiaLymphoma, Mantle-CellLymphoma, Follicular +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesCarna Biosciences IncBionova Pharmaceuticals (Shanghai) Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBionova Pharmaceuticals (Shanghai) LtdBioNova Pharmaceuticals LtdEvotec AG +[4] 
Inactive CompaniesAptuit (Verona) Srl
Active IndicationsWaldenstrom MacroglobulinemiaLymphoma, Mantle-CellLymphoma, Follicular +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A